Physician profile
Ted J Miller
NPI 1063483568
$7,773.97
in general payments reported to CMS, 2019-2025
43 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $796 · 2021: $1,528 · 2022: $1,394 · 2023: $1,383 · 2024: $1,123 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,799.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $701.48 | 2021-2025 | |
| Lilly USA, LLC | $674.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $595.52 | 2019-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $472.35 | 2019-2025 | |
| Pfizer INC. | $444.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $420.41 | 2019-2023 | Farxiga, Breztri, Lokelma |
| Xeris Pharmaceuticals, INC. | $307.51 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $286.33 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $171.23 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $151.34 | 2021 | |
| Esperion Therapeutics, INC. | $144.46 | 2020-2023 | Nexletol |
| Shield Therapeutics INC | $113.90 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $97.88 | 2024-2025 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.